CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced the completion of an additional $17.6 million round of ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., the developer of a revolutionary liquid biopsy platform that enables non-invasive diagnosis of serious diseases, aiming to reduce or ...

Exosome Diagnostics recently announced the launch of ExoDx Lung(ALK), a liquid biopsy platform that allows for non-invasive detection of biomarkers and potentially negates the need for a tissue biopsy ...

WASHINGTON and NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical ...

The exosome diagnostic and therapeutic market was valued at US$ 41.6.33 million in 2019 and is expected to grow at a CAGR of 32.2% from 2020 to 2027 to reach US$ 358.91 million 2027. According to The ...

Waltham, MA, March 21, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., is thrilled to announce the appointment of Dr. Grannum Sant as Head of Medical Affairs. As an internationally recognized ...

DUBLIN, May 30, 2019 /PRNewswire/ -- The "Exosome Diagnostics and Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report represents a current and ...

Exosome Diagnostics, Inc., the developer of a revolutionary liquid biopsy platform that enables non-invasive diagnosis of serious diseases, aiming to reduce or eliminate the need for tissue biopsies, ...

NEW YORK, Sept. 19, 2013 /PRNewswire/ -- Exosome Diagnostics today announced it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) for biomarker discovery and validation ...

MINNEAPOLIS, March 18, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract ...